Traditionally, treatment for colorectal cancer meant surgery, often leaving patients with a colostomy bag for life. But Patty ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.

“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The eighth stock on our list of best biotech ...

Takeda Canada Inc. ("Takeda") is pleased to announce that Ontario Drug Benefit (ODB) include FruzaqlaTM (fruquintinib ...

A small U.S. study of rectal cancer patients with a certain mutation found that every single person treated with an immunotherapy drug had their cancer "disappear" without the need for further ...

Guzmán, P. and Halpern, M. (2026) Effects of Treatment Delays on Colorectal Cancer Survival. Journal of Cancer Therapy, 17, ...

FOX21's Loving Living Local speaks with leading experts and a colorectal cancer survivor about how biomarker testing is ...

The University of Wisconsin–Madison and Immuto Scientific have teamed up to explore new therapeutic targets in colorectal cancer. According to the University of Wisconsin School of Medicine and ...

Kelly Spill didn’t cry when she was diagnosed with stage III rectal cancer at age 28. She held her emotions together when her surgeon told her that she might not be able to carry another baby — ...

Cancer is killing far fewer people in early and mid‑adulthood than it did a generation ago, a public‑health success story ...

Researchers note that toxin appeared to concentrate its effects within tumour tissue and did not cause any harmful inflammation in mice, such as effects on body weight, functions of vital organs and ...